ACE2 News and Research

RSS

Neutralizing responses to infection relatively common in COVID-19

A new study has shown that severe coronavirus disease 2019 (COVID-19) is associated with unique B cell receptor (BCR) signatures and multiclonal neutralizing responses against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

Researchers identify a promising method to stop COVID-19 infection

While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact.

8 Oct 2020

Study: New viral mutations would not impact the efficacy of Covid-19 vaccine candidates

Vaccines currently being developed for Covid-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologist.

8 Oct 2020

The Native Antigen Company introduces ten new SARS-CoV-2 specific antibodies

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19.

8 Oct 2020

SARS-CoV-2 spike protein may induce analgesia

A recent study published in the journal Pain in October 2020 adds another piece to the puzzle, showing that the virus is capable of dulling pain pathways. This may contribute to its early and extensive spread.

7 Oct 2020

New clinical report on brain changes in deceased COVID-19 patients

German researchers published a report on a series of cases on post mortem findings of COVID-19 patients who succumbed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection along with neurological complications. Their study titled “Neuropathology of patients with COVID-19 in Germany: a post-mortem case series” is published in the latest issue of The Lancet Neurology.

6 Oct 2020

Using virus-like particles to study SARS-CoV-2 assembly, budding, and entry

In a recent preprint paper published on the bioRxiv server, researchers from the Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, IN, discuss their efforts to assess the 4 SARS-CoV-2 structural proteins for their ability to produce VLPs from human cells to create a competent system for BSL-2 studies of SARS-CoV-2.

6 Oct 2020

Plasma ACE2 concentration associated with increased risk of major cardiovascular events

A team of scientists at the Population Health Research Institute, Hamilton Health Sciences, and McMaster University, Hamilton, in Ontario, Canada, revealed that increased plasma ACE2 levels in the blood could indicate a higher risk of major cardiovascular events. The study is published in the journal The Lancet.

6 Oct 2020

Chronic illnesses promote active SARS-CoV-2 infection via suppressed mucosal immunity

A recent paper published in the preprint server medRxiv in September 2020 discusses the “clinically relevant variation in the expression of COVID-19-related genes”, which is associated with the host and environmental factors, as well as host genetic factors.

6 Oct 2020

Cats and dogs are low risk for SARS-CoV-2 transmission to humans

Researchers from the College of Veterinary Medicine and Biomedical Sciences, Colorado State University studied the possible transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among domestic cats and dogs.

5 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Development of a coarse-grained model of SARS-CoV-2 virion

A team of scientists of the University of Chicago and the University of California San Diego has developed a coarse-grained (CG) model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virion. The model can be used as a valuable resource to perform multiscale simulations of the SARS-CoV-2 virion. The study is currently available on the bioRxiv* preprint server.

5 Oct 2020

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Researchers in the United States and Canada have discovered a monoclonal antibody that potently neutralizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

5 Oct 2020

New findings could improve investigation of T cell response to COVID-19

Researchers in the United States have made an important discovery about the processing and presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral peptides that provides a better understanding of the immune response to coronavirus disease 2019 (COVID-19) and may help facilitate the design of improved vaccines.

5 Oct 2020

Study confirms SARS-CoV-2 spike glycoprotein promotes a hyper-inflammatory immune response

A group of researchers from Australia and China recently demonstrated how SARS-CoV-2 spike glycoprotein subunit 1 can induce a pro-inflammatory signaling pathway (leading to cytokines deployment and epithelial damage in human bronchial epithelial cells), but also highlighted the potential of peptide-based antivirals in tackling this novel coronavirus.

5 Oct 2020

Macrophage subgroups may play pivotal role in COVID-19 lethality

Many researchers are attempting to identify risk factors for severe or critical COVID-19. A recent paper in the journal Medical Hypotheses in September 2020 suggests that macrophage class activation is one of the factors that determine the clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

5 Oct 2020

Advanced model reveals dynamic motions of SARS-COV-2 spike-shielding glycans

A recent paper published on the preprint server bioRxiv in September 2020 discusses the dynamic interactions of the spike protein glycan shield, which may be of great value in developing therapeutic compounds to fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Oct 2020